The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Monoclonal Gammopathy Followup in Hematology

Risk stratified surveillance for monoclonal gammopathy of undetermined significance

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Monoclonal Gammopathy Followup in Hematology?

Monoclonal gammopathy of undetermined significance is defined by serum monoclonal protein under thirty grams per liter, bone marrow plasma cells under ten percent, and absence of myeloma defining events such as anemia, kidney injury, hypercalcemia, or lytic bone lesions. It is found in about three percent of adults over fifty.

Risk of progression to multiple myeloma, smoldering myeloma, light chain amyloidosis, or Waldenstrom macroglobulinemia averages one percent per year and depends on monoclonal protein size, isotype, and the free light chain ratio. The Mayo risk model stratifies low, intermediate, and high risk patients.

Followup intervals depend on risk. Low risk patients undergo testing every six months for one year then annually with serum protein electrophoresis, immunofixation, free light chains, complete blood count, calcium, and creatinine. Higher risk patients need closer monitoring and bone imaging at baseline.

Symptoms

Asymptomatic detection on protein studies
Mild fatigue from hyperviscosity
Bone pain when progression occurs
Recurrent infections with hypogammaglobulinemia
Peripheral neuropathy in immunoglobulin M cases

Risk Factors

Older age above fifty
African ancestry
Family history of plasma cell dyscrasia
Chronic immune stimulation
Pesticide and benzene exposure

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • When monoclonal protein is detected on screening
  • When new bone pain develops
  • When cytopenia or kidney injury appears
  • When abnormal free light chain ratio emerges
  • When neuropathy progresses unexpectedly

Treatment Methods

01
Initial workup with serum and urine protein studies
02
Free light chain assay and immunofixation
03
Complete blood count calcium and creatinine
04
Bone imaging in higher risk patients
05
Risk stratification with the Mayo model
06
Periodic surveillance based on risk category
07
Referral to hematology when progression is suspected

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.